Meet the Investigators:
New Agents and Strategies in the Management of Ovarian Cancer

CME Information

TARGET AUDIENCE

This activity is intended for medical oncologists, gynecologic oncologists and other healthcare providers involved in the treatment of ovarian cancer (OC).

OVERVIEW OF ACTIVITY

The American Cancer Society estimates that 22,440 new cases of OC will be diagnosed in the United States in 2017 and 14,080 individuals will die of the disease. For this reason, significant financial and intellectual resources have been invested over the past few decades in attempts to better understand the natural history of the disease, identify genetic and other factors responsible for its proliferation and develop novel therapies with the potential to significantly improve outcomes for patients. The successes yielded by this rational approach to the design and evaluation of new therapies have culminated in a number of FDA approvals and clinical trials attempting to document the efficacy of new agents across multiple OC populations. These same successes have given rise to clinical and research questions for practicing clinicians regarding the therapeutic management of this disease.

These video proceedings from a CME symposium held during the 2017 ASCO Annual Meeting feature discussions with leading OC researchers regarding actual patient cases and related clinical research findings. By providing information on the latest research developments and their potential application to routine practice, this activity is designed not only to improve clinicians' knowledge of recent data related to the rapidly evolving ovarian oncology treatment landscape but also to provide them with practical perspectives to help them become better and more effective caregivers.

LEARNING OBJECTIVES

- Review clinical investigator perspectives on the selection of validated genetic testing platforms for patients with OC and on the implications of these findings for long-term treatment planning.
- Appreciate the recent FDA approval of niraparib as maintenance therapy for patients with recurrent, platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer, and safely integrate this agent into routine clinical practice.
- Develop an understanding of the efficacy data and toxicity profiles of approved and investigational PARP inhibitors for patients with advanced OC to effectively formulate protocol and nonresearch treatment recommendations for these individuals.
- Evaluate available Phase III data investigating the efficacy of olaparib as maintenance therapy for patients with BRCA mutation-positive, recurrent, platinum-sensitive OC who are responding to platinum-based chemotherapy.
- Recognize the mechanisms of action, emerging efficacy data and toxicity profiles of novel targeted agents and immunotherapeutic approaches under investigation in OC, and prioritize clinical trial opportunities for appropriate patients.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 1.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third

parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at **ResearchToPractice.com/Privacy-Policy** for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at **ResearchToPractice.com/ASCOOvarian17/CME**.

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Michael Birrer, MD, PhD
Director, UAB Comprehensive Cancer Center
University of Alabama at Birmingham
Birmingham, Alabama

Advisory Committee: Roche Laboratories Inc.

Joyce F Liu, MD, MPH
Director of Clinical Research, Gynecologic Oncology
Assistant Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: AstraZeneca Pharmaceuticals LP, Tesaro Inc; **Consulting Agreement:** AstraZeneca Pharmaceuticals LP.

Mansoor Raza Mirza, MD
Medical Director, Nordic Society of Gynecologic Oncology
Chief Oncologist, Department of Oncology
Rigshospitalet, Copenhagen University Hospital
Copenhagen, Denmark

Board of Directors: Karyopharm Therapeutics, Metamark Genetics Inc, Sera Prognostics; **Consulting Agreements:** Advaxis Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Cerulean Pharma Inc, Clovis Oncology, Genmab, Karyopharm Therapeutics, Novocure, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc; **Paid Research:** AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Pfizer Inc, Roche Laboratories Inc, Tesaro Inc.

MODERATOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, ImmunoGen Inc and Tesaro Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2017

Expiration date: August 2018

Select Publications

A phase 3 placebo-controlled study of carboplatin/paclitaxel with or without concurrent and continuation maintenance veliparib (PARP inhibitor) in subjects with previously untreated stages III or IV high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. NCT02470585

Aghajanian C et al. **Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.** *Gynecol Oncol* 2015;139(1):10-6.

Aghajanian C et al. **OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.** *J Clin Oncol* 2012;30(17):2039-45.

Bell-McGuinn KM et al. **A phase I study of continuous veliparib in combination with IV carboplatin/paclitaxel or IV/IP paclitaxel/cisplatin and bevacizumab in newly diagnosed patients with previously untreated epithelial ovarian, fallopian tube, or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.** *Proc ASCO* 2015;**Abstract 5507**.

Coleman RL et al. **Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial.** *Lancet Oncol* 2017;18(6):779-91.

Coleman RL et al. **A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study.** *Gynecol Oncol* 2015;137(3):386-91.

FORWARD I: A randomized, open label phase 3 study to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) versus investigator's choice of chemotherapy in women with folate receptor alpha positive advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer. NCT02631876

Frey MK, Pothuri B. **Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: A review of the literature.** *Gyneco Oncol Res Pract* 2017;4:4.

Hamanishi J et al. **Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer.** *J Clin Oncol* 2015;33(34):4015-22.

Kristeleit RS et al. **Clinical activity of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC) and a BRCA mutation (BRCAmut): Analysis of pooled data from Study 10 (parts 1, 2a, and 3) and ARIEL2 (parts 1 and 2).** *Proc ESMO* 2016;**Abstract 856O**.

Mirza MR et al. **A randomized, double-blind phase 3 trial of maintenance therapy with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer (ENGOT-OV16/NOVA trial).** *Proc ESMO* 2016;**Abstract LBA3_PR**.

Mirza MR et al. **Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.** *N Engl J Med* 2016;375(22):2154-64.

Moore KN et al. **IMGN853 (mirvetuximab soravtansine), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC): Single agent activity in platinum-resistant epithelial ovarian cancer (EOC) patients (pts).** *Proc ASCO* 2016;**Abstract 5567**.

Norquist BM et al. **Inherited mutations in women with ovarian carcinoma.** *JAMA Oncol* 2016;2(4):482-90.